Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008476
Chunk: 113

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 113
---
                | 23.20 |     |              | 2.77 |
| Granted                        |     |           | 3,280,281 |     |                  |  1.40 |     |              | 5.00 |
| Outstanding, December 31, 2024 |     | $         | 3,464,281 |     | $                |  1.89 |     |              | 4.67 |

The intrinsic value of the warrants as of December 31, 2024 is less than $0.1 million. All of the outstanding warrants are exercisable as of December 31, 2024.

Equity Incentive Plan

The Company’s 2018 Equity Incentive Plan (the “2018 Plan”) provides for equity incentives to be granted to employees, executive officers, directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of not less than the fair market value of the underlying shares as determined pursuant to the 2018 Plan, restricted stock awards, other stock-based awards, or any combination of the foregoing. The 2018 Plan is administered by the Company’s compensation committee. The Company has reserved 3,000,000 shares of common stock for issuance under the 2018 Plan. As of December 3 1, 2024,1,174,684 shares have been granted, net of forfeitures, under the 2018 Equity Incentive Plan, of which90,045 shares have vested.

Restricted Stock Units

The Company may grant restricted stock units (“RSU”) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to the fair market value of one share of our common stock. Subject to the provisions of the 2018 Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually in one third increments from the date of appointment.

During the years ended December 31, 2024 and 2023, pursuant to agreements with directors, officers and consultants, 1,102,410and 32,415RSUs with a value of $0.9million and $0.4million were granted, respectively.Compensation expense for the vesting RSUs were as follows: